Vitamin D3: research breakthroughs and therapeutic use

Автор(и)

  • М Pohorila Mechnikov Institute of Microbiology and Immunology,
  • A Martynov Mechnikov Institute of Microbiology and Immunology,
  • E Romanova Mechnikov Institute of Microbiology and Immunology,
  • N Іgumnova Mechnikov Institute of Microbiology and Immunology,
  • Т Sidorenko Mechnikov Institute of Microbiology and Immunology,
  • V Yukhimenko Mechnikov Institute of Microbiology and Immunology,
  • O Shcherbak Mechnikov Institute of Microbiology and Immunology,

Ключові слова:

Vitamin D3, cholecalciferol, VDR, infection, pulmonary disease, tuberculosis, innate immunity, adoptive immunity, antimicrobial effect

Анотація

Vitamin D3 (cholecalciferol), the natural form of vitamin D, is produced in the skin from 7-dehydrocholesterol. The synthesis of vitamin D in the skin is the most important source of vitamin D. Vitamin D can also be taken through nutrition, in the diet, but it is present in only a few food sources, containing relevant levels of vitamin D. 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] is the hormonally active form of vitamin D.  Novel researches show it generates a number of extraskeletal biological responses including inhibition of variety types cancer progression, effects on cardiovascular disorders and mediates a protection against a number of inflammatory, autoimmune and infection diseases The biological actions of 1,25(OH)2D3 are mediated by the VDR. The genomic mechanism of 1,25(OH)2D3 action involves the direct binding of 1,25(OH)2D3 activated VDR/RXR to specific DNA sequences  in and around target genes resulting in either activation or repression of transcription [7] VDR modulates the expression of genes involved in immune function and cytokine production. The VDR and CYP27B1, the enzyme located in kidneys and target organs, are present in immune competent cells, bronchial and pulmonary epithelial cells, among others, and is up-regulated following the ligation of specific toll-like receptors by extracellular pathogens, implicating vitamin D in innate immunity. By binding the VDR, calcitriol induces several endogenous antimicrobial peptides (AMP) in monocytes, neutrophils and epithelial cells including cathelicidin LL-37, α-defensin,β defensing and neutrophil gelatinase-associated lipocalin and up-regulates nitric oxide (NO) synthase. Since the inflammatory response associated with infections such influenza, pneumonia and sepsis increases both clinical severity and mortality, the ability to reduce inflammation may allow vitamin D to decrease mortality and disease burden in certain infections. Notwithstanding the width of possible vitamin D application field, which being known now, large-scale clinical trials are still demanded. Our review has the aim to summarize current scientific understanding of Vitamin D3 effects on the immunological field with the focus on its capacity to enhance the anti-infection and anti-inflammatory immune reactivity. Vitamin D and Tuberculosis. Vitamin D has been widely studied in the prevention and treatment of tuberculosis. Current studies were focused on how calcitriol enhances the antimicrobial effects of macrophages and monocytes – important effector cells, fighting against pathogens such as Mycobacterium tuberculosis (MBT). Several studies tracked the impact of vitamin D on cytokines that promote anti-MTB activity and the resolution of infection. Suppression of antigen-stimulated pro-inflammatory cytokines, attenuation of anti-inflammatory cytokines, and a more rapid treatment-induced resolution of lymphopenia and monocytosis associated with TB infection occurred following 100,000 IU doses of vitamin D3 given monthly for 4 months. Conversion of sputum smear or sputum culture was used to measure response to treatment in several studies, though only sputum culture conversion is independently linked to long-term risk of treatment failure and relapse. Also it was found  that 10,000 IU of vitamin D3 given daily for 6 weeks to significantly increase sputum smear conversion (100 % in the treatment group vs. 76,7 % in the placebo group, p=0,002). IFN-γ levels were impacted variably: 2 doses of vitamin D3  (600,000 IU)) led to increasing of IFN-γ expression , while a single 100,000 IU dose of vitamin D2 showed no change .  Negative results in some studies could be explained by variability of the Taq1 vitamin D receptor genotype polymorphism. It was shown that significantly accelerated conversion is appropriate of patients who have a tt genotype compared to those with the Tt or TT genotype. But these results were not confirmed by another study, where were founded no interaction between VDR genotype effectiveness of vitamin D.  Several trials show vitamin D given largely as an adjunctive therapy with traditional anti-tuberculosis regimens in a variety of dose and dosing schedule has some impact on clearance of MBT from sputum in the wide number randomized controlled multicenter trials of patients with active tuberculosis infection. Patients with infection of MBT with different strains of tuberculosis can take benefits from Vitamin D3 consumption due to its effect on the clearance of MTB from sputum and on dampening the inflammatory response or anthropometric changes that may help tuberculosis patients recover. A significant microbiologic effect of vitamin D3 was indicated in several trials that, also, sustained by in vitro tests, where its antimycobacterial effects in cultured macrophages was shown. Antimycobacterial effect is provided enhances the expression of the anti-microbial peptide human cathelicidin (hCAP18) in cultured macrophages. The clinical benefit after high vitamin D3 doses administrating to patients does not depend of their vitamin D3 marked deficiency. The cause of this variation remains unexplained. The role of genetic polymorphisms in the vitamin D receptor, or in the multiple enzymes involved in its metabolism in vitD3 effectiveness remains unproved. Measurement of calcitriol-induced antimycobacterial activity in ex vivo whole blood culture in future studies may help in understanding the functional effects of specific genetic polymorphisms. So, big attention will be required in future studies to determine mechanism of vitamin effect on patients with tuberculosis.

Посилання

Teichmann A, Dutta PC, Staffas A, Jägerstad M. Sterol and vitamin D2 concentrations in cultivated and wild grown mushrooms: effects of UV irradiation // LWT Food Sci. Technol. 2007 Vol. 40. P. 815–822.

Bikle D, Adams J, Christakos S. Vitamin D: production, metabolism and clinical requirements. In: Primer Metab Bone Dis, edited by Rosen C, editor. Hoboken, NJ: Wiley. 2013. P. 235–245.

Zehnder D, Evans KN, Kilby MD. et al. The ontogeny of 25-hydroxyvitamin D(3) 1alpha-hydroxylase expression in human placenta and decidua // Am J Pathol. 2002. Vol. 161(1). P.105-114.

Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects // Physiological Reviews. 2016. Vol. 96(1). P. 365-408.

Margolis RN, Christakos S, Ann NY. The nuclear receptor superfamily of steroid hormones and vitamin D gene regulation // Acad Sci. 2010. Vol. 1192. P. 208-214.

Feldman D, Malloy J, Bonekey P. Mutations in the vitamin D receptor and hereditary vitamin D-resistant rickets // Rep. 2014. Vol. 3. P. 510.

Pike JW, Meyer MB. Fundamentals of vitamin D hormone-regulated gene expression // J Steroid Biochem Mol Biol. 2014. Vol.144. Pt A. P. 5-11.

Carlberg C, Campbell MJ. Vitamin D receptor signaling mechanisms: integrated actions of a well-defined transcription factor // Steroids. 2013. Vol. 78(2). P.127-136.

Bhalla AK, Amento EP, Clemens TL, et al. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation // J Clin Endocrinol Metab. 1983. Vol. 57(6). P.1308–1310.

Stumpf WE, Sar M, Reid FA, et al. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid // Science. 1979. Vol. 206(4423). P.1188–1190.

Yim S, Dhawan P, Ragunath C, et al. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D(3) // J Cyst Fibros. 2007. Vol. 6(6). Vol. 403–410.

Hansdottir S, Monick MM, Hinde SL, et al. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense // J Immunol. 2008. Vol. 181(10). P.7090–7099.

Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response // Science. 2006. Vol. 311(5768). P. 1770–1773.

White JH. Vitamin D signaling, infectious diseases, and regulation of innate immunity// Infect Immun. 2008. Vol. 76(9). P. 3837–3843.

Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response // Science. 2006. Vol. 311(5768). P. 1770–1773.

Wang TT, Nestel FP, Bourdeau V, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression // J Immunol. 2004. Vol. 173(5). P. 2909–2912.

Ciornei CD, Sigurdardottir T, Schmidtchen A, et al. Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of human cathelicidin LL-37 // Antimicrob Agents Chemother. 2005. Vol. 49(7). P. 2845–2850.

Thijssen HH, Janssen CA, Drittij-Reijnders MJ. The effect of S-warfarin administration on vitamin K 2,3-epoxide reductase activity in liver, kidney and testis of the rat // Biochem Pharmacol. 1986. Vol. 35(19). P. 3277–3282.

Ramanathan B, Davis EG, Ross CR, et al. Cathelicidins: microbicidal activity, mechanisms of action, and roles in innate immunity // Microbes Infect. 2002. Vol. 4(3). P.361–372.

Gropp R, Frye M, Wagner TO, et al. Epithelial defensins impair adenoviral infection: implication for adenovirus-mediated gene therapy // Hum Gene Ther. 1999. Vol. 10(6). P. 957–964.

Klotman ME, Chang TL. Defensins in innate antiviral immunity // Nat Rev Immunol. 2006. Vol. 6(6). P. 447–456.

Sly LM, Lopez M, Nauseef WM, et al. 1alpha,25-Dihydroxyvitamin D3-induced monocyte antimycobacterial activity is regulated by phosphatidylinositol 3-kinase and mediated by the NADPH-dependent phagocyte oxidase // J Biol Chem. 2001. P. 276(38). P. 35482–35493.

Rook GA, Hernandez-Pando R, Lightman SL. Hormones, peripherally activated prohormones and regulation of the Th1/Th2 balance // Immunol Today. 1994. Vol. 15(7). P.301–303.

Cox FE, Liew FY. T-cell subsets and cytokines in parasitic infections // Immunol Today. 1992. Vol. 13(11). P .445–448.

Thorne KJ, Mazza G. Eosinophilia, activated eosinophils and human schistosomiasis // J Cell Sci. 1991. Vol. 98(Pt 3). P. 265–270.

Diaz A, Allen JE. Mapping immune response profiles: the emerging scenario from helminth immunology // Eur J Immunol. 2007. Vol. 37(12). P. 3319–3326.

Romani L. Cell mediated immunity to fungi: a reassessment // Med Mycol. 2008. Vol. 46(6). P. 515–529.

Kobasa D, Takada A, Shinya K, et al. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus // Nature. 2004. P. 431(7009). P.703–707.

Cheung CY, Poon LL, Lau AS, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? // Lancet. 2002. Vol. 360(9348). P. 1831–1837.

Kellum JA, Kong L, Fink MP, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study // Arch Intern Med. 2007. Vol. 167(15). P. 1655–1663.

Yende S, D'Angelo G, Kellum JA, et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis // Am J Respir Crit Care Med. 2008. Vol. 177(11). P. 1242–1247.

Jeng L., Yamshchikov AV, Judd SE, Blumberg HM, Martin GS, Ziegler TR, Tangpricha V. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis // J. Transl. Med. 2009. Vol. 7. P. 28.

Grimnes G, Figenschau Y, Almås B, Jorde R. Vitamin D, insulin secretion, sensitivity, and lipids: results from a case-control study and a randomized controlled trial using hyperglycemic clamp technique // Diabetes 2011. Vol. 60. P. 2748-2757.

Shab-Bidar S, Neyestani TR, Djazayery A, Eshraghian MR, Houshiarrad A, Kalayi A, Shariatzadeh N, Khalaji N, Gharavi A. Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes // Diabetes Metab Res Rev 2012. Vol. 28. P. 424-430.

Kampmann U, Mosekilde L, Juhl C, Moller N, Christensen B, Rejnmark L, Wamberg L, Orskov L. Effects of 12weeks high dose vitamin D3 treatment on insulin sensitivity, beta cell function, and metabolic markers in patients with type 2 diabetes and vitamin D insufficiency - a double-blind, randomized, placebo-controlled trial // Metabolism 2014. Vol. 63. P. 1115-1124.

Bucharles S, Barberato SH, Stinghen AE, et al. Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism // J Ren Nutr 2012. Vol. 22. P. 284-291.

Sokol SI, Srinivas V, Crandall JP, et al. The effects of vitamin D repletion on endothelial function and inflammation in patients with coronary artery disease // Vasc Med. 2012. Vol. 17. P. 394-404.

Alvarez JA, Zughaier SM, Law J, et al. Effects of high-dose cholecalciferol on serum markers of inflammation and immunity in patients with early chronic kidney disease // Eur J Clin Nutr 2013. Vol. 67. P. 264-269.

Breslavsky A, Frand J, Matas Z, Boaz M, Barnea Z, Shargorodsky M. Effect of high doses of vitamin D on arterial properties, adiponectin, leptin and glucose homeostasis in type 2 diabetic patients // Clin Nutr. 2013. Vol. 32. P.970-975.

Witham MD, Crighton LJ, Gillespie ND, Struthers AD, McMurdo ME. The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial // Circ Heart Fail 2010. Vol. 3. P.195-201.

Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation // J Neuroimmunol. 2003. Vol. 134. P.128-132

Pappa HM, Mitchell PD, Jiang H, et al. Maintenance of optimal vitamin D status in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing two regimens // J Clin Endocrinol Metab. 2014. Vol. 99. P.3408-3417.

Grossmann RE, Zughaier SM, Liu S, Lyles RH, Tangpricha V. Impact of vitamin D supplementation on markers of inflammation in adults with cystic fibrosis hospitalized for a pulmonary exacerbation // Eur J Clin Nutr. 2012. Vol. 66. P. 1072-1074.

Hewison M. An update on vitamin D and human immunity // Clin. Endocrinol. 2012. Vol. 76. P.315–325.

Lemire JM, Adams JS, Kermani-Arab V, Bakke AC, et al. 1,25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro // J. Immunol. 1985. Vol. 134. P. 3032–3035.

Cantorna MT. Mechanisms underlying the effect of vitamin D on the immune system // Proc. Nutr. Soc. 2011. Vol. 69. P. 286–289.

Baeke F, Korf H, Overbergh L, Verstuyf A, et al. The vitamin D analog, TX527, promotes a human CD4+CD25highCD127low regulatory T cell profile and induces a migratory signature specific for homing to sites of inflammation // J. Immunol. 2011. Vol. 186. P.132–142.

Palmer MT, Lee YK, Maynard CL, Oliver JR, et al. Lineage-specific effects of 1,25-dihydroxyvitamin D3 on the development of effector CD4 T cells // J. Biol. Chem. 2011. Vol. 286. P. 997–1004.

Boonstra A, Barrat FJ, Crain C, et al. 1α,25-dihydroxyvitamin D3 has a direct effect on naive CD4+T cells to enhance the development of Th2 cells // J. Immunol. 2001. Vol. 167. P. 4974–4980.

Joshi S, Pantalena L, Liu XK, Sarah L, et al. 1,25-Dihydroxyvitamin D3 ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A // Mol. Cell. Biol. 2011. Vol. 31. P. 3653–3669.

Jeffery LE, Burke F, Mura M, Zheng Y, et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3 // J. Immunol. 2009. Vol. 183. P.5458–5467.

Rudensky AY. Regulatory T cells and foxP3 // Immunol. Rev. 2011. Vol. 241. P. 260–268.

Ardalan MR, Maljaei H, Shoja MM, Piri AR, et al. Calcitriol started in the donor, expands the population of CD4+ CD25+ T cells in renal transplant recipients // Transplant. Proc. 2007. Vol. 39. P.951–953.

Prietl B., Pilz S., Wolf M., Tomaschitz A., Obermayer-Pietsch B., Graninger W., Pieber T.R. Vitamin D supplementation and regulatory T cells in apparently healthy subjects: Vitamin D treatment for autoimmune diseases? // Isr. Med. Assoc. J. 2010. Vol. 12. P.136–139.

Bock G, Prietl B, Mader JK, Höller E, et al. The effect of vitamin D supplementation on peripheral regulatory T cells and β cell function in healthy humans: A randomized controlled trial // Diabetes Metab. Res. Rev. 2011. Vol. 25. P. 942–945.

Gabbay MAL, Sato MN, Finazzo C, Duarte AJS, Dib SA. Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual β-cell function in new-onset type 1 diabetes mellitus // Arch. Pediatr. Adolesc. Med. 2012. Vol. 166. P. 601–607.

Ferrari M, Schenk K, Papadopoulou C, et al. Serum 25-hydroxy vitamin D and exercise capacity in COPD // Thorax. 2011. Vol. 66(6). P. 544–545.

Wilkinson RJ, Llewelyn M, Toossi Z, et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet. 2000;355(9204):618–21.

Holick MF. High prevalence of vitamin D inadequacy and implications for health // Mayo Clin Proc. 2006. Vol. 81(3). P.353–373.

Aloia JF, Li-Ng M. Re: epidemic influenza and vitamin D // Epidemiol Infect. 2007. Vol. 135(7). P.1095–1096.

Urashima M, Segawa T, Okazaki M, et al. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren // Am J Clin Nutr. 2010. Vol. 91(5). P.1255–1260.

Majak P, Olszowiec-Chlebna M, Smejda K, et al. Vitamin D supplementation in children may prevent asthma exacerbation triggered by acute respiratory infection // J Allergy Clin Immunol. 2011. Vol. 127(5). P. 1294–1296.

Bergman P, Norlin AC, Hansen S, et al. Vitamin D3 supplementation in patients with frequent respiratory tract infections: a randomised and double-blind intervention study // BMJ Open. 2012.2(6)

Camargo CA, Ganmaa D, Frazier AL, et al. Randomized trial of vitamin D supplementation and risk of acute respiratory infection in Mongolia // Pediatrics. 2012 . Vol. 130(3). P.561–567.

Lehouck A, Mathieu C, Carremans C, et al. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial // Ann Intern Med. 2012. Vol. 156(2). P.105–114.

Baeke F., Takiishi T., Korf H., Gysemans C., Mathieu C. Vitamin D: Modulator of the immune system. Curr. Opin. Pharmacol. 2010. Vol. 10. P. 482–496.

Wang T, Nestel FP, Bourdeau V, Nagai Y, et al. Cutting edge: 1,25-Dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression // J. Immunol. 2004. Vol. 173. P. 2909–2912.

Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3 // FASEB J. 2005. Vol. 19. P.1067–1077.

White JH. Vitamin D metabolism and signaling in the immune system // Rev. Endocr. Metab. Disord. 2012. Vol. 13. P.21–29.

Liu PT, Stenger S, Li H, Wenzel L, Tan BH, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response // Science. 2006. Vol. 311. P. 1770–1773.

Edfeldt K, Liu PT, Chun R, Fabri M, Schenk M, et al. T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin D metabolism // Proc. Natl. Acad. Sci. 2010. Vol. 107. P. 22593–22598.

Coussens AK, Wilkinson RJ, Hanifa Y, et al. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment // Proc Natl Acad Sci. 2012. Vol. 109(38). P.15449–15454.

Ganmaa D, Giovannucci E, Bloom BR, et al. Vitamin D, tuberculin skin test conversion, and latent tuberculosis in Mongolian school-age children: a randomized, double-blind, placebo-controlled feasibility trial // American Journal of Clinical Nutrition. 2012. Vol. 96(2). P. 391–396.

Kota SK, Jammula S, Kota SK, et al. Effect of vitamin D supplementation in type 2 diabetes patients with pulmonary tuberculosis // Diabetes Metab Syndr. 2011. Vol. 5(2). P. 85–9.

Martineau AR, Timms PM, Bothamley GH, et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial // Lancet. 2011. Vol. 377(9761). P. 242–250.

Salahuddin N, Ali F, Hasan Z, et al. Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis // BMC Infect Dis. 2013. Vol. 13. P. 22.

Morcos MM, Gabr AA, Samuel S, et al. Vitamin D administration to tuberculous children and its value // Boll Chim Farm. 1998. Vol. 137(5). P. 157–164.

Nursyam EW, Amin Z, Rumende CM. The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion // Acta Med Indones. 2006. Vol. 38(1) P. 3–5.

Ralph AP, Waramori G, Pontororing GJ, et al. L-arginine and vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebo-controlled trial // PLoS One. 2013. Vol. 8(8):e70032.

Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial // Lancet. 2002. Vol. 360(9332). P. 528–534.

Mily A, Rekha RS, Kamal SM, et al. Oral intake of phenylbutyrate with or without vitamin D3 upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosis // BMC Pulm Med. 2013. Vol. 13. P. 23.

Crowle AJ, Ross EJ, May MH. Inhibition by 1,25(OH)2-vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages // Infect Immun. 1987. Vol. 55(12). P. 2945-2950.

##submission.downloads##

Опубліковано

2019-12-23

Як цитувати

Pohorila М., Martynov, A., Romanova, E., Іgumnova N., Sidorenko Т., Yukhimenko, V., & Shcherbak, O. (2019). Vitamin D3: research breakthroughs and therapeutic use. Анали Мечниковського Інституту, (4), 13–20. вилучено із https://journals.uran.ua/ami/article/view/188841

Номер

Розділ

Дослідні статті